2014
DOI: 10.1007/s12070-014-0805-4
|View full text |Cite
|
Sign up to set email alerts
|

Cavernous Sinus Thrombosis of Nasal Origin in Children

Abstract: Cavernous sinus thrombosis is a rare presentation. Early diagnosis and aggressive treatment are required to prevent morbidity and mortality. Nasal infections can give rise to serious intracranial complications. Presented here is a case series of cavernous sinus thrombosis of nasal septic origin. The purpose of this article is to report our experience in pediatric patients with this illness to ascertain a clinical course and outcomes for further clinical application. Eight (08) cases of nasalseptic origin of ca… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
5
1
3

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(9 citation statements)
references
References 19 publications
0
5
1
3
Order By: Relevance
“…2,3 Infarction was less prevalent than in our cohort, with only 1 child demonstrating infarct. In an adult series, 4 of 7 patients developed neurological impairment, including 1 with vision loss.…”
Section: Discussioncontrasting
confidence: 70%
See 1 more Smart Citation
“…2,3 Infarction was less prevalent than in our cohort, with only 1 child demonstrating infarct. In an adult series, 4 of 7 patients developed neurological impairment, including 1 with vision loss.…”
Section: Discussioncontrasting
confidence: 70%
“…The incidence has likely decreased significantly because of the use of antibiotics. [1][2][3] CST has been reported to cause CAN and vasospasm, 4,5 embolic infarcts, and large territory infarction from hypoperfusion. 4,6 The standard acute treatment for childhood cerebral venous sinus thrombosis is typically anticoagulation therapy (ACT) 7 although the optimal treatment for children with the subset of CST remains largely uncertain.…”
mentioning
confidence: 99%
“…S. Varshney и соавт. [8] считают, что впервые ТКС как осложнение эпидуральной и субдуральной инфекции описал Bright в 1831 г.…”
Section: обзорыunclassified
“…Антибиотик группы карбапенемов: меропенем 6 г/сут внутривенно [23]. Адекватной антибактериальной терапией при ТКС является комбинация ванкомицина и цефтриаксона/ампициллина-сульбактама/пиперациллина-тазобактама [8,12,23]. Сульбактам и тазобактам -лекарственные средства, подавляющие действие β-лактамазы, используются в комбинации с другими антибиотиками.…”
Section: обзорыunclassified
See 1 more Smart Citation